1546-1547 / 2351
Why should we care?
DAHANCA 18: concomitant chemoradiotherapy
p16pos
93%
Oropharynx: HPV/p16 status (n=141)
100
Oropharynx
83%
Dahanca 18: Site-specific LCR (n=227)
100
(%)
p16neg
63%
50
75
Survival (%)
Larynx
Hypopharynx
74%
67%
50
75
nal control
Events All
p16pos 8 112
25
Overall
Cavum Oris
46%
25
Loco-regio
p16neg
HR=5.70 (2.24-14.48)
10 29
P<0.0001
0
At risk
0 12 24 36 48 60
Time after treatment (months)
0
At risk
0 12 24 36 48 60
Time after treatment (months)
29
26
22
12
6
3
p16neg
112
109
105
75
46
14
p16pos
23
15
10
4
0
0
Cavum Oris
26
20
15
12
8
3
Hypopharynx
150 134 128
86
53
17
Oropharynx
28
22
19
16
9
2
Larynx
Benzten et al Acta Oncol 2015